Please do not leave this page until complete. This can take a few moments.
A six-week, combined phase trial of the novel drug candidate dasotraline by Sunovion Pharmaceuticals Inc. found it was generally well-tolerated and demonstrated a statistically significant difference compared to placebo when given to children with attention-deficit/hyperactivity disorder.
The Marlborough drugmaker administered once-daily doses of dasotraline to 342 children ages 6-12. Children given doses of four milligrams per deciliter of dasotraline saw statistically significant, clinically relevant results, according to Sunovion. Just over 9 percent of participants discontinued the study due to treatment-emergent adverse effects, including insomnia, decreased appetite and weight loss.
“We recognize that there are still significant gaps in the treatment of ADHD, particularly a need for products that provide sustained therapeutic effects. We look forward to the overall results of the dasotraline development program, which is evaluating this potential therapy in children and adults with ADHD,” said Antony Loebel, executive vice president and chief medical officer at Sunovion and head of global clinical development for Sumitomo Dainippon Pharma Group.
Stay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Sign upWorcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
SubscribeWorcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
See Digital EditionStay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Worcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
Worcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments